2GQG

X-ray Crystal Structure of Dasatinib (BMS-354825) Bound to Activated ABL Kinase Domain

Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.40 Å
  • R-Value Free: 0.273 
  • R-Value Work: 0.208 

wwPDB Validation   3D Report Full Report


This is version 1.3 of the entry. See complete history. 


Literature

The Structure of Dasatinib (BMS-354825) Bound to Activated ABL Kinase Domain Elucidates Its Inhibitory Activity against Imatinib-Resistant ABL Mutants

Tokarski, J.S., Newitt, J., Chang, C.Y.J., Cheng, J.D., Wittekind, M., Kiefer, S.E., Kish, K., Lee, F.Y.F., Borzilerri, R., Lombardo, L.J., Xie, D., Zhang, Y., Klei, H.E.

(2006) Cancer Res 66: 5790-5797

  • DOI: 10.1158/0008-5472.CAN-05-4187
  • Primary Citation of Related Structures:  
    2GQG

  • PubMed Abstract: 

    • Chronic myeloid leukemia (CML) is caused by the constitutively activated tyrosine kinase breakpoint cluster (BCR)-ABL. Current frontline therapy for CML is imatinib, an inhibitor of BCR-ABL. Although imatinib has a high rate of clinical success in early phase CML, treatment resistance is problematic, particularly in later stages of the disease, and is frequently mediated by mutations in BCR-ABL ...

    Chronic myeloid leukemia (CML) is caused by the constitutively activated tyrosine kinase breakpoint cluster (BCR)-ABL. Current frontline therapy for CML is imatinib, an inhibitor of BCR-ABL. Although imatinib has a high rate of clinical success in early phase CML, treatment resistance is problematic, particularly in later stages of the disease, and is frequently mediated by mutations in BCR-ABL. Dasatinib (BMS-354825) is a multitargeted tyrosine kinase inhibitor that targets oncogenic pathways and is a more potent inhibitor than imatinib against wild-type BCR-ABL. It has also shown preclinical activity against all but one of the imatinib-resistant BCR-ABL mutants tested to date. Analysis of the crystal structure of dasatinib-bound ABL kinase suggests that the increased binding affinity of dasatinib over imatinib is at least partially due to its ability to recognize multiple states of BCR-ABL. The structure also provides an explanation for the activity of dasatinib against imatinib-resistant BCR-ABL mutants.

    Organizational Affiliation: 

    Bristol-Myers Squibb Company, Pharmaceutical Research Institute, Princeton, New Jersey, USA. john.tokarski@bms.com



Macromolecules
Find similar proteins by: 
(by identity cutoff)  |  Structure
Entity ID: 1
MoleculeChainsSequence LengthOrganismDetailsImage
Proto-oncogene tyrosine-protein kinase ABL1A, B278Homo sapiensMutation(s): 1 
Gene Names: ABL1, ABL, JTK7
EC: 2.7.10.2
Find proteins for P00519 (Homo sapiens)
Explore P00519 
Go to UniProtKB:  P00519
NIH Common Fund Data Resources
PHAROS:  P00519
GTEx:  ENSG00000097007
Protein Feature View
Expand
  • Reference Sequence
Small Molecules
Ligands 2 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
1N1
Query on 1N1
Download Ideal Coordinates CCD File 
 C [auth A], D [auth B]N-(2-CHLORO-6-METHYLPHENYL)-2-({6-[4-(2-HYDROXYETHYL)PIPERAZIN-1-YL]-2-METHYLPYRIMIDIN-4-YL}AMINO)-1,3-THIAZOLE-5-CARBOXAMIDE
C22 H26 Cl N7 O2 S
ZBNZXTGUTAYRHI-UHFFFAOYSA-N		 Ligand Interaction
GOL
Query on GOL
Download Ideal Coordinates CCD File 
 E [auth B]GLYCEROL
C3 H8 O3
PEDCQBHIVMGVHV-UHFFFAOYSA-N		 Ligand Interaction
Modified Residues  1 Unique
IDChainsTypeFormula2D DiagramParent
PTR
Query on PTR		A, BL-PEPTIDE LINKINGC9 H12 N O6 PTYR
External Ligand Annotations 
IDBinding Affinity (Sequence Identity %)
1N1Kd:  0.30000001192092896   nM  BindingDB
1N1Kd:  1.100000023841858   nM  BindingDB
1N1IC50:  3   nM  BindingDB
1N1Kd:  0.05999999865889549   nM  BindingDB
1N1Kd:  0.9599999785423279   nM  BindingDB
1N1Kd:  0.17000000178813934   nM  BindingDB
1N1Kd:  120   nM  BindingDB
1N1IC50:  0.800000011920929   nM  BindingDB
1N1Kd:  0.05000000074505806   nM  BindingDB
1N1Kd:  0.5   nM  BindingDB
1N1IC50:  4.199999809265137   nM  BindingDB
1N1Kd:  0.5299999713897705   nM  BindingDB
1N1IC50:  7.599999904632568   nM  BindingDB
1N1Kd:  0.03999999910593033   nM  BindingDB
1N1IC50:  0.20000000298023224   nM  BindingDB
1N1IC50:  1   nM  BindingDB
1N1IC50:  0.14000000059604645   nM  BindingDB
1N1IC50:  10   nM  BindingDB
1N1Kd:  59   nM  BindingDB
1N1IC50:  1000   nM  BindingDB
1N1Kd:  0.10000000149011612   nM  BindingDB
1N1IC50:  4   nM  BindingDB
1N1IC50:  700   nM  BindingDB
1N1Kd:  2.0999999046325684   nM  BindingDB
1N1IC50:  14   nM  BindingDB
1N1IC50:  220   nM  BindingDB
1N1Kd:  40   nM  BindingDB
1N1Kd:  0.019999999552965164   nM  BindingDB
1N1Kd:  0.699999988079071   nM  BindingDB
1N1IC50:  0.5   nM  BindingDB
1N1Kd:  2   nM  BindingDB
1N1Kd:  0.7200000286102295   nM  BindingDB
1N1IC50:  0.25999999046325684   nM  BindingDB
1N1Kd:  1.2000000476837158   nM  BindingDB
1N1Kd:  1   nM  BindingDB
1N1IC50:  17   nM  BindingDB
1N1Kd:  0.029999999329447746   nM  BindingDB
1N1EC50:  0.03999999910593033   nM  BindingDB
1N1IC50:  15   nM  BindingDB
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.40 Å
  • R-Value Free: 0.273 
  • R-Value Work: 0.208 
  • Space Group: P 43 21 2
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 105.192α = 90
b = 105.192β = 90
c = 111.1γ = 90
Software Package:
Software NamePurpose
DENZOdata reduction
SCALEPACKdata scaling
AMoREphasing
CNSrefinement
PDB_EXTRACTdata extraction
ADSCdata collection

Structure Validation

View Full Validation Report


View more in-depth experimental data

Entry History 

Deposition Data

  • Deposited Date: 2006-04-20 
  • Released Date: 2006-11-21 
    • Deposition Author(s): Klei, H.E.

Revision History  (Full details and data files)

  • Version 1.0: 2006-11-21
    Type: Initial release
  • Version 1.1: 2008-05-01
    Changes: Version format compliance
  • Version 1.2: 2011-07-13
    Changes: Non-polymer description, Version format compliance
  • Version 1.3: 2017-10-18
    Changes: Refinement description